Request Demo

Last update 08 May 2025

Urate nephropathy

Last update 08 May 2025

Basic Info

Synonyms

URIC ACID NEPHROPATHY, Urate nephropathy, Urate nephropathy (disorder)

+ [5]

Introduction-

Clinical Trials associated with Urate nephropathy

ChiCTR2400084757

/ SuspendedNot ApplicableIIT

A randomized controlled trial of massage with aromatic plant essential oil on pain in patients with uric acid nephropathy complicated with acute gout

Start Date01 Jun 2024

Sponsor / Collaborator-

CTR20233194

/ CompletedNot Applicable

别嘌醇缓释胶囊在中国健康受试者空腹状态下的单中心、随机、开放、两制剂、四周期、两序列、完全重复交叉生物等效性研究

[Translation] A single-center, randomized, open-label, two-dose, four-period, two-sequence, fully repeated crossover bioequivalence study of allopurinol sustained-release capsules in Chinese healthy subjects under fasting condition

主要研究目的：以别嘌醇的主要药代动力学参数（AUC和Cmax）为生物等效性评价指标，在中国健康受试者空腹状态下评估受试制剂（黑龙江澳利达奈德制药有限公司生产的别嘌醇缓释胶囊，规格0.25g，商品名：奥迈必利）和参比制剂（G.L.Pharma GmbH持证的别嘌醇缓释胶囊，规格250mg，商品名：Gichtex®）的生物等效性。次要研究目的：观察空腹状态下受试制剂和参比制剂的安全性。

[Translation]

The main research purpose: To evaluate the bioequivalence of the test preparation (allopurinol sustained-release capsules produced by Heilongjiang Aolidanide Pharmaceutical Co., Ltd., specification 0.25g, trade name: Omapride) and the reference preparation (allopurinol sustained-release capsules certified by G.L.Pharma GmbH, specification 250mg, trade name: Gichtex®) in the fasting state of healthy Chinese subjects using the main pharmacokinetic parameters (AUC and Cmax) of allopurinol as bioequivalence evaluation indicators. Secondary research purpose: To observe the safety of the test preparation and the reference preparation in the fasting state.

Start Date10 Oct 2023

Sponsor / Collaborator

Heilongjiang Aolidanide Pharmaceutical Co., Ltd.

CTR20231803

/ RecruitingNot Applicable

别嘌醇缓释胶囊在健康受试者中随机、开放、两制剂、单剂量、两序列、四周期、完全重复交叉的空腹和餐后状态下的生物等效性正式试验

[Translation] A randomized, open-label, two-formulation, single-dose, two-sequence, four-period, fully repeated crossover formal bioequivalence study of allopurinol extended-release capsules in healthy subjects under fasting and fed conditions

主要研究目的：研究空腹/餐后状态下单次口服受试制剂别嘌醇缓释胶囊（规格：250mg，湖北广辰药业有限公司）与参比制剂别嘌醇缓释胶囊（Gichtex®，规格：250mg；G.L. Pharma GmRH持证）在人体内的药代动力学，评价空腹/餐后状态口服两种制剂的生物等效性。次要研究目的：评价中国健康受试者空腹/餐后单次口服受试制剂别嘌醇缓释胶囊和参比制剂别嘌醇缓释胶囊（Gichtex®）后的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of the test preparation Allopurinol Sustained Release Capsules (Specification: 250mg, Hubei Guangchen Pharmaceutical Co., Ltd.) and the reference preparation Allopurinol Sustained Release Capsules (Gichtex®, Specification: 250mg; G.L. Pharma GmRH licensed) in humans after a single oral administration in the fasting/fed state, and to evaluate the bioequivalence of the two preparations in the fasting/fed state. The secondary purpose of the study is to evaluate the safety of the test preparation Allopurinol Sustained Release Capsules and the reference preparation Allopurinol Sustained Release Capsules (Gichtex®) after a single oral administration in Chinese healthy subjects in the fasting/fed state.

Start Date12 Jul 2023

Sponsor / Collaborator

Hubei Guangchen Pharmaceutical Co Ltd

100 Clinical Results associated with Urate nephropathy

100 Translational Medicine associated with Urate nephropathy

0 Patents (Medical) associated with Urate nephropathy

407

Literatures (Medical) associated with Urate nephropathy

01 Jun 2025·Bioorganic Chemistry

Jiangniaosuan formula inhibits hyperuricemia-induced apoptosis of renal tubular epithelial cells via ROS/HIF-1α/EZH2 pathway: A network pharmacology analysis and experimental validation

Article

Author: Wang, Chuanxu ; Gao, Jiandong ; Zhou, Jiabao ; Zhang, Xuming ; Yang, Feng ; Wu, Zhiyuan

OBJECTIVEThis study aimed to explore the main chemical components of Jiangniaosuan Formula (JNSF), the therapeutic effect of JNSF on hyperuricemia (HUA) mice, and the underlying mechanism by which JNSF inhibits renal tubular epithelial cell apoptosis.METHODSUltra Performance Liquid Chromatography-Quadrupole-Time of Flight Mass Spectrometry (UPLC-Q-TOF-MS) was used to analyze the chemical composition of JNSF and its serum metabolites. Network pharmacology was performed to predict the potential target genes and pathways. In vitro and in vivo models were established to verify the lower serum uric acid (SUA) and renal protective effects.RESULTSUPLC-Q-TOF-MS identified 61 chemical compounds in JNSF and 56 metabolites in serum after oral administration. Network pharmacology suggested that Hypoxia-Inducible Factor 1-Alpha (HIF-1α), Cysteine-dependent Aspartate-specific Protease-3 (Caspase-3) and B-cell Lymphoma 2 (Bcl-2) might be the therapeutic targets of JNSF for the HUA treatment and JNSF may exert the therapeutic effect on uric acid nephropathy (UAN) through regulating HIF-1α signaling pathway and apoptosis pathway. In vivo experiments showed that JNSF could reduce SUA, protect renal function and tubular function, alleviate renal interstitial edema and fibrosis, reduce the expression of Reactive Oxygen Species (ROS), HIF-1α and Enhancer of Zeste Homolog 2 (EZH2), and inhibit cell apoptosis in HUA mice. In vitro experiments demonstrated that JNSF reversed apoptosis induced by EZH2 overexpression plasmid. Furthermore, we found that UA could promote the binding of HIF-1α to EZH2 protein and its promoter, enhancing EZH2 transcription, suggesting that JNSF could alleviate the progression of HUA-induced kidney injury by inhibiting the activation of ROS/HIF-1α/EZH2 pathway.CONCLUSIONJNSF may attenuate HUA-induced renal injury by inhibiting apoptosis through the downregulation of ROS/HIF-1α/EZH2 pathway.

01 Mar 2025·Journal of Cellular and Molecular Medicine

Inhibition of METTL3 Attenuates Renal Fibrosis by Upregulating ABCG2 m6A Modifications via IGF2BP2‐Dependent Mechanisms in Hyperuricemic Nephropathy

Article

Author: Zu, Tong ; Yu, Yue ; Zhang, Kuo ; Wang, Xian ; Yang, Hang ; Song, Xiuxiu ; Yang, Yaru ; Li, Shuangjian ; Jin, Juan ; Wang, Jie ; Ying, Jie

ABSTRACTHyperuricemia has been linked to kidney problems including hyperuricemic nephropathy (HN), which is characterised by inflammation and fibrosis in the kidneys. HN is frequently observed in patients with chronic gout. However, the causes of HN are not fully understood and effective treatments are limited. The status of RNA m6A, expression, and location of METTL3 in the kidney was evaluated in mice with HN. The mechanism of the METTL3‐associated ABCG2 downregulation was further studied in mTEC cells and a potassium oxazinate + adenine‐induced mice model and adeno‐associated virus 9 (AAV9)‐mediated METTL3 silencing mice. Expressions of ABCG2, α‐SMA, collagen‐1, TGF‐β1, IL‐1β, IL‐6, and TNF‐α were analysed using real‐time PCR and western blotting. Hyperuricemia led to elevated m6A levels and METTL3 expression in mouse kidneys. METTL3 was mainly located in mTEC cells. METTL3‐specific inhibitor STM2457 alleviated uric acid‐induced inflammatory and fibrotic responses in mTEC cells. Mechanistically, ABCG2 was identified as a target of METTL3 by RNA sequencing. The stability of ABCG2 was decreased through the binding of IGF2BP2 (insulin‐like growth factor 2 binding protein 2) to its m6A‐modified stop codon regions. Silencing or inhibition of METTL3 significantly reduced uric acid‐induced cell injury and increased ABCG2 expression, leading to uric acid excretion. In vivo data showed that AAV9‐mediated METTL3 silencing significantly alleviated renal dysfunction and fibrosis in HN mice. Our study provides the first evidence that METTL3 regulates uric acid excretion by controlling the m6A levels of ABCG2 through the binding of IGF2BP2, and inhibiting METTL3 can effectively alleviate kidney damage caused by hyperuricemia, showing potential as a therapy for HN.

01 Mar 2025·Nutrition, Metabolism and Cardiovascular Diseases

Two still unanswered questions about uric acid and cardiovascular prevention: Is a specific uric acid cut-off needed? Is hypouricemic treatment able to reduce cardiovascular risk?

Review

Author: Binaghi, Giulio ; Borghi, Claudio ; Colivicchi, Furio ; Temporelli, Pier Luigi ; Daus, Francesca ; Maloberti, Alessandro ; Oliva, Fabrizio ; De Censi, Lorenzo ; Colombo, Valentina ; Abrignani, Maurizio Giuseppe ; Grimaldi, Massimo ; Gabrielli, Domenico

AIMSThe most frequent consequence of elevated uric acid (UA) levels is the development of gout and urate kidney disease. Besides these effects, several studies have investigated the association between hyperuricemia and cardiovascular (CV) disease. High serum UA has been identified as an important determinant of all-cause and CV mortality and CV events (acute and chronic coronary syndrome, stroke and peripheral artery disease). Despite the high number of publications on this topic, there are two questions that are still unanswered: do we need a specific CV cut-off of serum UA to better refine the CV risk? Is urate lowering treatment (ULT) able to reduce CV risk in asymptomatic patients? In this review, we will focus on these two points.DATA SYNTHESISAlthough no doubt exists that the relationship between CV events starts at lower levels than the actually used cut-off, different papers found dissimilar cut-offs. Furthermore, heterogeneity is present depending on the specific CV events evaluated and none of the found cut-off have been tested in external populations (in order to confirm its discriminatory capacity). Furthermore, only few randomized clinical trials on the role of hypouricemic agents in reducing the CV risk have been published giving heterogeneous results. The last published one (ALL-HEART) has strong limitations, that we will deeply discuss.CONCLUSIONSA definitive answer to the two questions is impossible with the actually published paper but, over identifying current gaps in knowledge we try to individuate how they can be overruled.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Urate nephropathy

Basic Info

Related

Analysis